As debate intensifies in the U.S. over abortion, a new survey finds nearly half of all women support alternatives to visiting a medical facility in order to obtain the abortion medicine to terminate pregnancies. And the findings suggest there is potential to expand access to abortion care, if regulators can be persuaded to loosen regulations governing access to the medicine, according to the researchers.

Currently, women in the U.S. must obtain mifepristone at a doctor’s office, clinic, or hospital under a risk management program required by the Food and Drug Administration. The restrictions were imposed when the drug was approved in 2000 and stipulate Mifeprex may not be sold in pharmacies and health care providers must complete a certification process.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy